The study aimed to evaluate HBV vaccination rates among US psoriasis patients, considering the risk of HBV reactivation with biologic psoriasis treatments. Data from the National Health and Nutrition Examination Survey (2009-2014) revealed that only 32% of psoriasis patients received all three HBV vaccine doses, compared to 35% in the general population. While psoriasis patients showed slightly lower vaccination rates, multivariable logistic regression did not find a significant difference. Given the potential complications of HBV infections, especially with biologic therapy, ensuring psoriasis patients are vaccinated before immunosuppressive treatment is vital.

Dermatologists play a key role in advocating for proper vaccination among psoriasis patients, particularly those on biologic or immunosuppressive therapy, to prevent conditions like HBV. Promoting vaccine compliance and ensuring patients are well-informed about their immunization status can help reduce the risk of HBV reactivation and other vaccine-preventable diseases in this population.

Reference: Edem W, Banihani S, Martin A, Wu JJ. Hepatitis B vaccination in patients with psoriasis. J Am Acad Dermatol. 2023 Oct;89(4):851-853. doi: 10.1016/j.jaad.2023.06.023. Epub 2023 Jun 19. PMID: 37343831.